Financial Results, Upcoming Presentations, and Stock Price Movements - Research Report on Valeant Pharmaceuticals, St. Jude

    Financial Results, Upcoming Presentations, and Stock Price Movements -
  Research Report on Valeant Pharmaceuticals, St. Jude Medical, AstraZeneca,
                         Stryker, and Smith & Nephew

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant
Pharmaceuticals International Inc. (NYSE: VRX), St. Jude Medical, Inc. (NYSE:
STJ), AstraZeneca plc (ADR) (NYSE: AZN), Stryker Corporation (NYSE: SYK) and
Smith & Nephew plc (ADR) (NYSE: SNN). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Valeant Pharmaceuticals International Inc. Research Report

On October 31, 2013, Valeant Pharmaceuticals International Inc. (Valeant)
reported its Q3 2013 financial results. The Company's total revenues increased
74.4% YoY to $1.5 billion during the quarter. Net loss attributable to Valeant
was $973.2 million or $2.92 per diluted share in Q3 2013, compared to net
income attributable to Valeant of $7.6 million or $0.02 per diluted share in
Q3 2012. J. Michael Pearson, Chairman and CEO of Valeant, said, "Despite an
unexpected early launch of a generic Retin-A Micro, significant headwinds this
quarter from foreign exchange movements, and the demands of a major
integration, we managed to beat expectations and position Valeant for a
terrific fourth quarter and a strong 2014. I thank our team, both at Valeant
and our new colleagues from Bausch + Lomb, for their commitment, diligence,
and focus on execution. I am confident that our strategic focus on
diversification, durable assets, key geographies, and low risk R&D will
continue to benefit our shareholders as we look forward to continuing our
track record of outperformance." The Full Research Report on Valeant
Pharmaceuticals International Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/9fdd_VRX]

--

St. Jude Medical, Inc. Research Report

On November 1, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that
it will present at the 2013 Credit Suisse Healthcare Conference on November
13, 2013, in Scottsdale, Arizona. St. Jude Medical reported that its Chairman,
President, and CEO Dan Starks will address the conference at 8:00 a.m. PT. The
Company also informed that the presentation will be webcast live at its
website. The Full Research Report on St. Jude Medical, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b338_STJ]

--

AstraZeneca plc (ADR) Research Report

On October 31, 2013, AstraZeneca plc (ADR) (AstraZeneca) reported its Q3 2013
financial results. The Company's revenue declined 6.5% YoY to $6.3 billion
during the quarter. According to the Company, Q3 2013 revenue declined due to
the ongoing impact from products with recent losses of exclusivity. Profit for
the quarter stood at $1.2 billion and diluted earnings per ordinary share came
in at $0.99, compared to profit of $1.5 billion and diluted earnings per
ordinary share of $1.20 in Q3 2012. The Company stated that EPS in Q3 2013
included $0.18 per share benefit from the reversal of an intangible asset
impairment related to the initiation of Phase III clinical trials of olaparib.
The Full Research Report on AstraZeneca plc (ADR) - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/09cc_AZN]

--

Stryker Corporation Research Report

On November 1, 2013, Stryker Corporation's stock (Stryker) rose 0.23%, ending
the day at $74.03. Over the previous three trading sessions, shares of Stryker
declined 0.67% compared to the S&P 500 which declined 0.58% during the same
period. The Full Research Report on Stryker Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5b34_SYK]

--

Smith & Nephew plc (ADR) Research Report

On October 31, 2013, Smith & Nephew plc (ADR) (Smith & Nephew) reported its Q3
2013 financial results. The Company's revenue increased 7.9% YoY to $1.0
billion during the quarter. Attributable profit declined 7.6% YoY to $122
million and diluted EPS declined 8.2% YoY to $13.5 in Q3 2013. Commenting on
the results, Olivier Bohuon, CEO of Smith & Nephew said, "Smith & Nephew had a
strong third quarter, delivering 5% growth in revenue and 10% growth in
trading profit on an underlying basis. Our global performance in Hip and Knee
Implants improved following successful new product introductions and increased
investment. We generated 20% revenue growth across our Emerging and
International Markets. Advanced Wound Management significantly outperformed
its segment with another excellent quarter from Healthpoint Biotherapeutics,
which we have now rebranded as Smith & Nephew." He added, "Our markets remain
tough, but through implementing our strategic priorities we are meeting these
challenges, investing where we see the greatest opportunities for growth, and
successfully reshaping the Group for long-term success." The Full Research
Report on Smith & Nephew plc (ADR) - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/eed3_SNN]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)